 Keytruda has proved to be MRKs leading sales driver, projected to contribute a significant 35.38 of FY2022 revenues at 20.9B. Given the early clinical success of MRNA and Keytruda combo, we reckon the former has a similarly bright prospect through the next decade, aided by the flu and RSV vaccines. 